Literature DB >> 15728517

Tumor cells deactivate human monocytes by up-regulating IL-1 receptor associated kinase-M expression via CD44 and TLR4.

Carlos del Fresno1, Karel Otero, Lourdes Gómez-García, Maria Carmen González-León, Llanos Soler-Ranger, Pablo Fuentes-Prior, Pedro Escoll, Rosa Baos, Luis Caveda, Felipe García, Francisco Arnalich, Eduardo López-Collazo.   

Abstract

Although blood monocytes possess significant cytotoxic activity against tumor cells, tumor-infiltrating monocytes are commonly deactivated in cancer patients. Monocytes pre-exposed to tumor cells show significantly decreased expression levels of TNF-alpha, IL-12p40, and IL-1R-associated kinase (IRAK)-1. Activation of the Ser/Thr kinase IRAK-1 is an important event in several inflammatory processes. By contrast, another IRAK family member, IRAK-M, negatively regulates this pathway, and is up-regulated in cultures of endotoxin-tolerant monocytes and in monocytes from septic patients within the timeframe of tolerance. In this study, we show that IRAK-M expression is enhanced at the mRNA and protein level in human monocytes cultured in the presence of tumor cells. IRAK-M was induced in monocytes upon coculturing with different tumor cells, as well as by fixed tumor cells and medium supplemented with the supernatant from tumor cell cultures. Moreover, blood monocytes from patients with chronic myeloid leukemia and patients with metastasis also overexpressed IRAK-M. Low concentrations of hyaluronan, a cell surface glycosaminoglycan released by tumor cells, also up-regulated IRAK-M. The induction of IRAK-M by hyaluronan and tumor cells was abolished by incubation with anti-CD44 or anti-TLR4 blocking Abs. Furthermore, down-regulation of IRAK-M expression by small interfering RNAs specific for IRAK-M reinstates both TNF-alpha mRNA expression and protein production in human monocytes re-exposed to a tumor cell line. Altogether, our findings indicate that deactivation of human monocytes in the presence of tumor cells involves IRAK-M up-regulation, and this effect appears to be mediated by hyaluronan through the engagement of CD44 and TLR4.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15728517     DOI: 10.4049/jimmunol.174.5.3032

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  52 in total

1.  α-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming.

Authors:  Pu-Ste Liu; Haiping Wang; Xiaoyun Li; Tung Chao; Tony Teav; Stefan Christen; Giusy Di Conza; Wan-Chen Cheng; Chih-Hung Chou; Magdalena Vavakova; Charlotte Muret; Koen Debackere; Massimiliano Mazzone; Hsien-Da Huang; Sarah-Maria Fendt; Julijana Ivanisevic; Ping-Chih Ho
Journal:  Nat Immunol       Date:  2017-07-17       Impact factor: 25.606

2.  CD44 regulates macrophage recruitment to the lung in lipopolysaccharide-induced airway disease.

Authors:  John W Hollingsworth; Zhuowei Li; David M Brass; Stavros Garantziotis; Sarah H Timberlake; Andrew Kim; Imtaz Hossain; Rashmin C Savani; David A Schwartz
Journal:  Am J Respir Cell Mol Biol       Date:  2007-04-19       Impact factor: 6.914

3.  Loss of the innate immunity negative regulator IRAK-M leads to enhanced host immune defense against tumor growth.

Authors:  Qifa Xie; Lu Gan; Jianxia Wang; Ingred Wilson; Liwu Li
Journal:  Mol Immunol       Date:  2007-05-02       Impact factor: 4.407

Review 4.  The involvement of the interleukin-1 receptor-associated kinases (IRAKs) in cellular signaling networks controlling inflammation.

Authors:  Lorna Ringwood; Liwu Li
Journal:  Cytokine       Date:  2008-01-30       Impact factor: 3.861

5.  Soluble CD83 Inhibits T Cell Activation by Binding to the TLR4/MD-2 Complex on CD14+ Monocytes.

Authors:  Joe M Horvatinovich; Elizabeth W Grogan; Marcus Norris; Alexander Steinkasserer; Henrique Lemos; Andrew L Mellor; Irina Y Tcherepanova; Charles A Nicolette; Mark A DeBenedette
Journal:  J Immunol       Date:  2017-02-13       Impact factor: 5.422

Review 6.  Immunoparalysis and adverse outcomes from critical illness.

Authors:  W Joshua Frazier; Mark W Hall
Journal:  Pediatr Clin North Am       Date:  2008-06       Impact factor: 3.278

7.  Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases.

Authors:  Ileana S Mauldin; Nolan A Wages; Anne M Stowman; Ena Wang; Walter C Olson; Donna H Deacon; Kelly T Smith; Nadedja Galeassi; Jessica E Teague; Mark E Smolkin; Kimberly A Chianese-Bullock; Rachael A Clark; Gina R Petroni; Francesco M Marincola; David W Mullins; Craig L Slingluff
Journal:  Cancer Immunol Immunother       Date:  2016-08-13       Impact factor: 6.968

8.  Squamous carcinoma cells influence monocyte phenotype and suppress lipopolysaccharide-induced TNF-alpha in monocytes.

Authors:  Aroonwan Lam-ubol; Dustin Hopkin; Elena M Letuchy; Zoya B Kurago
Journal:  Inflammation       Date:  2010-08       Impact factor: 4.092

9.  Extracellular HSP110 skews macrophage polarization in colorectal cancer.

Authors:  Kevin Berthenet; Christophe Boudesco; Ada Collura; Magali Svrcek; Sarah Richaud; Arlette Hammann; Sebastien Causse; Nadhir Yousfi; Kristell Wanherdrick; Laurence Duplomb; Alex Duval; Carmen Garrido; Gaetan Jego
Journal:  Oncoimmunology       Date:  2016-04-22       Impact factor: 8.110

10.  Engagement of CD44 by hyaluronan suppresses TLR4 signaling and the septic response to LPS.

Authors:  Jun Muto; Kenshi Yamasaki; Kristen R Taylor; Richard L Gallo
Journal:  Mol Immunol       Date:  2009-09-24       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.